Thyrotropin-Releasing Hormone

PreclinicalSmall molecule

NNational Center for Research Resources (NCRR)

Thyrotropin-Releasing Hormone is one of 64 small molecule programs targeting Hypothyroidism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypothyroidismActive, not recruiting

Lung DiseaseActive, not recruiting

HypothyroidismPreclinical

Active, not recruiting

Lung DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

74 competitors in Lung Disease

#DrugCompanyPhaseTrials

Colcrys

Alnylam Pharmaceuticals

Duragesic

1 3

Esbriet

LLegacy Health System

Approved

1 4

Viagra

VViatris Specialty LLC

Approved

1 5

Proair HFA

GGlaxo Dba Glaxosmithkline

Xolair

1 7

Kalydeco

Vertex Pharmaceuticals

Phase 3

1 8

Rituxan

Roche

Phase 3

1 9

Mycobutin

Pfizer

Phase 3

1 10

Biaxin

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pregnant Women1 trial

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery

Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004778·1,090 enrolled

Hypothyroidism1 trial

Mechanistic Study of Subclinical Hypothyroidism In the Elderly

Completed·UUniversity of Pennsylvania·N/A·NCT02399475·14 enrolled

Lung Disease1 trial

Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00004840·996 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Thyrotropin-Releasing Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thyrotropin-Releasing Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thyrotropin-Releasing Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Center for Research Resources (NCRR) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Center for Research Resources (NCRR)

Thyrotropin-Releasing Hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pregnant Women1 trial

Hypothyroidism1 trial

Lung Disease1 trial

References

Drug Info

Quick Facts

Related News